Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21710325 | 0.90 | USP25 (0.48) | USP28USP25 | |
| SCHEMBL21710328 | 0.89 | USP28 (0.51) | USP28USP25 | |
| SCHEMBL21710324 | 0.86 | USP25 (0.53) | USP28USP25 | |
| SCHEMBL25794174 | 0.86 | USP25 (0.53) | USP28USP25 | |
| SCHEMBL23517541 | 0.84 | USP28 (0.48) | USP28USP25 | |
| SCHEMBL21685997 | 0.84 | USP28 (0.47) | USP28USP25 | |
| SCHEMBL21710424 | 0.84 | USP28 (0.48) | USP28USP25 | |
| SCHEMBL30741124 | 0.84 | USP28 (0.47) | USP28USP25 | |
| SCHEMBL21710321 | 0.82 | USP28 (0.53) | USP28USP25 | |
| SCHEMBL21710323 | 0.80 | USP28 (0.51) | USP28USP25 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252490-B2 | Inhibiting deubiquitinase USP25 and USP28 | VALO HEALTH, INC. (US) | 2025-03-18 | — | — | US | claimed |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | VALO HEALTH, INC. | 2021-06-17 | — | — | US | claimed |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | VALO HEALTH, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2020033709-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | USP28, USP25, USP30 | USP28 1/4885USP25 2/4885 |
| US-12252490-B2 | Inhibiting deubiquitinase USP25 and USP28 | USP28, USP25, USP30 | USP28 1/4885USP25 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.